Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:COLL NASDAQ:PTCT NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$38.10+3.6%$31.66$16.50▼$43.58$3.32BN/A47,688 shs6,463 shsCOLLCollegium Pharmaceutical$32.04+0.1%$29.90$23.23▼$42.29$1.03B0.64398,374 shs70,030 shsPTCTPTC Therapeutics$47.82+0.1%$48.49$29.02▼$58.38$3.79B0.5876,036 shs171,684 shsRAREUltragenyx Pharmaceutical$27.34+0.5%$36.12$26.85▼$60.37$2.58B0.26947,181 shs674,168 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+1.55%-11.10%+16.66%+94.81%+3,675,999,900.00%COLLCollegium Pharmaceutical-2.53%+1.36%+9.66%+18.43%+0.69%PTCTPTC Therapeutics-3.46%+0.21%-6.85%+2.89%+44.13%RAREUltragenyx Pharmaceutical-6.94%-31.00%-27.45%-22.24%-38.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/ACOLLCollegium Pharmaceutical4.2927 of 5 stars3.42.00.03.02.70.82.5PTCTPTC Therapeutics4.4116 of 5 stars4.31.00.04.42.70.81.3RAREUltragenyx Pharmaceutical4.374 of 5 stars4.51.00.03.82.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/ACOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7536.55% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$65.0035.93% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$83.64205.96% UpsideCurrent Analyst Ratings BreakdownLatest COLL, PTCT, RARE, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025RAREUltragenyx PharmaceuticalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$35.00 ➝ $34.007/14/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$65.00 ➝ $55.007/10/2025RAREUltragenyx PharmaceuticalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$88.00 ➝ $65.006/20/2025RAREUltragenyx PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.006/17/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/28/2025RAREUltragenyx PharmaceuticalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.005/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/9/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$64.00 ➝ $65.005/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M24.71N/AN/A$0.48 per share79.38COLLCollegium Pharmaceutical$664.28M1.55$12.05 per share2.66$7.10 per share4.51PTCTPTC Therapeutics$1.77B2.14N/AN/A($14.24) per share-3.36RAREUltragenyx Pharmaceutical$590.69M4.38N/AN/A$2.76 per share9.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/ACOLLCollegium Pharmaceutical$69.19M$1.2226.265.32N/A6.61%99.08%15.14%8/6/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.517.35N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)Latest COLL, PTCT, RARE, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27N/AN/AN/AN/AN/A8/6/2025Q2 2025COLLCollegium Pharmaceutical$1.88N/AN/AN/A$182.26 millionN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International3.241.261.26COLLCollegium Pharmaceutical3.301.081.01PTCTPTC TherapeuticsN/A3.893.85RAREUltragenyx PharmaceuticalN/A2.402.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/ACOLLCollegium PharmaceuticalN/APTCTPTC TherapeuticsN/ARAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/ACOLLCollegium Pharmaceutical2.51%PTCTPTC Therapeutics5.50%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.12 millionN/AN/ACOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionablePTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableRAREUltragenyx Pharmaceutical1,29494.54 million89.34 millionOptionableCOLL, PTCT, RARE, and AAPG HeadlinesRecent News About These CompaniesWilliam Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE)2 hours ago | insidermonkey.comFY2025 EPS Estimates for RARE Cut by Cantor FitzgeraldJuly 16 at 6:46 AM | marketbeat.comWilliam Blair Has Bearish Estimate for RARE FY2025 EarningsJuly 16 at 6:46 AM | marketbeat.comWedbush Analysts Decrease Earnings Estimates for RAREJuly 16 at 6:25 AM | marketbeat.comMorgan Stanley Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock PriceJuly 16 at 4:09 AM | americanbankingnews.comUltragenyx hit again, this time with a CRL in rare diseaseJuly 15 at 10:19 PM | bioworld.comBUltragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIAJuly 15 at 10:19 PM | msn.comUltragenyx Pharmaceutical (NASDAQ:RARE) Trading Down 5.7% on Analyst DowngradeJuly 15 at 11:57 AM | marketbeat.comUltragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIAJuly 15 at 9:31 AM | zacks.comQ4 EPS Forecast for Ultragenyx Pharmaceutical Cut by AnalystJuly 15 at 8:23 AM | marketbeat.comUltragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A RejectionJuly 14 at 10:14 AM | investors.comWedbush Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock PriceJuly 14 at 9:32 AM | marketbeat.comUltragenyx receives CRL from US FDA for UX111 AAV gene therapy to treat Sanfilippo syndrome type AJuly 14 at 9:27 AM | pharmabiz.comPUltragenyx receives complete response letter for UX111 BLAJuly 14 at 9:27 AM | finance.yahoo.comUltragenyx hit with FDA delay for gene therapy targeting rare childhood disorderJuly 14 at 9:27 AM | thepharmaletter.comTMorgan Stanley Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $55.00July 14 at 9:04 AM | marketbeat.comUltragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market SessionJuly 14 at 8:14 AM | benzinga.comEquities Analysts Set Expectations for RARE Q2 EarningsJuly 14 at 2:23 AM | marketbeat.comJanuary 2027 Options Now Available For Ultragenyx Pharmaceutical (RARE)July 13 at 6:22 PM | nasdaq.comUltragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green LightJuly 13 at 3:28 PM | insidermonkey.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Raised by Emerald Mutual Fund Advisers TrustJuly 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTesla’s Robotaxi Hype Fuels Bullish Price Targets to $500By Sam Quirke | June 30, 2025View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500Why Qualcomm’s Latest Price Target Can't Be IgnoredBy Sam Quirke | June 24, 2025View Why Qualcomm’s Latest Price Target Can't Be Ignored5 Hot Stocks With Summer Buybacks You Can Cash In OnBy Thomas Hughes | July 10, 2025View 5 Hot Stocks With Summer Buybacks You Can Cash In OnConagra at Rock Bottom: 7% Yield & Turnaround PoisedBy Thomas Hughes | July 13, 2025View Conagra at Rock Bottom: 7% Yield & Turnaround PoisedMP Materials Stock Booms on New Government PositioningBy Gabriel Osorio-Mazilli | July 14, 2025View MP Materials Stock Booms on New Government PositioningCOLL, PTCT, RARE, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$38.10 +1.34 (+3.65%) As of 11:49 AM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Collegium Pharmaceutical NASDAQ:COLL$32.04 +0.04 (+0.13%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.PTC Therapeutics NASDAQ:PTCT$47.82 +0.07 (+0.15%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Ultragenyx Pharmaceutical NASDAQ:RARE$27.34 +0.14 (+0.51%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
